Skip to main content
Erschienen in: Rheumatology International 10/2008

Open Access 01.08.2008 | Original Article

The association of anti-CCP antibodies with disease activity in rheumatoid arthritis

verfasst von: Münevver Serdaroğlu, Haşim Çakırbay, Orhan Değer, Sevil Cengiz, Sibel Kul

Erschienen in: Rheumatology International | Ausgabe 10/2008

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Antibodies to citrullinated proteins have been described in patients with rheumatoid arthritis (RA) and these appear to be the most specific markers of the disease. Our objective was to determine the frequency of antibodies to cyclic citrullinated peptides (CCPs) in patients with RA and the association of anti-CCP antibodies with disease activity, radiological erosions and HLA DR genotype. Forty patients with RA and 38 patients with fibromyalgia were included in this study. Serum samples were collected from both patient groups with RA and fibromyalgia. Anti-CCP was measured by the corresponding enzyme-linked immunosorbent assay. Additionally, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), disease activity score (DAS), visual analog scala (VAS), HLA genotype and radiographic information were determined in patients with RA. The rate of sensitivity and specificity of anti-CCP reactivity for the diagnosis RA were measured (sensitivity 50%, specificity100%). There is no significant difference between anti-CCP (+) and anti-CCP (−) RA patients for DAS28, VAS, ESR, CRP, disease duration, HLA genotype, and radiological assessment of hand. However, there was a significant difference between anti-CCP (+) and anti-CCP (−) RA patients for RF and the radiological assessment of left and right wrists (respectively, < 0.05, = 0.04, = 0.01). There was no significant correlation between anti-CCP antibody and ESR, CRP, VAS, DAS 28 or radiological assessment. A small but significant correlation was found between RF and anti-CCP antibody (= 0.02, r = 0.35).

Introduction

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by chronic and erosive poliarthritis caused by abnormal growth of sinovial tissue or pannus, and causes irreversible joint disability. It is the most common inflammatory arthritis, affecting from 0.5 to 1% of the general population worldwide, with a female/male ratio of 2.5:1. The disease may appear at any age, but it is most common among those aged from 40 to 70 years and its incidence increases with age [1]. Apart from pain, RA is associated with reduction of functional capacity, and increased comorbidity and mortality [2, 3].
For decades, the diagnosis of RA has been primarily based on clinical manifestations. However, especially during the first few months of the disease, the 1987 revised criteria of the American College of Rheumatology (ACR) are rarely met [4]. About one-third of the patients with persistent arthritis do not fulfill the classification criteria, so it is often difficult to diagnose RA in the very early stages of the disease [5]. On the other hand, numerous studies have shown that substantial irreversible joint damage occurs within the first 2 years [6, 7]. In many cases, irreversible damage of the joint cartilage has already occurred by the time laboratory and radiological parameters have confirmed the clinical daignosis RA [8].
Because of the highly variable and unpredictable course of the disease, current therapeutic strategies in RA are increasingly aggressive regimens early in the course of the disease. Therefore, diagnostic tests with high-specificity are desirable for deciding on the optimal treatment [9].
So far, serological support in the diagnosis of RA was mainly based on the presence of rheumatoid factors (RF) [10]. RF can be detected in up to 70–80% of RA patients [11]. The ACR criteria for RA diagnosis include the presence of RF, a decision that has contributed to the widely routine use of this test as a diagnostic marker for RA in most clinical laboratories. However, these antibodies are not very specific for RA and can also be detected in other rheumatic diseases, infectious diseases, and even in 3–5% of apparently healthy individuals [10, 12].
In recent years, many studies on antibodies against cyclic citrullinated peptide (CCP) have demonstrated that these antibodies are highly specific and predictive for RA [13] that they can be detected years before onset [14], and also that they are associated with joint destruction [15]. Furthermore, the presence or absence of these antibodies seems to be a stable trait [16]. Anti-CCP antibodies are detected in SE-positive as well as in SE-negative RA patients. Carriership of SE alleles in RA is associated with the presence of anti-CCP antibodies [17].
This article investigates the sensitivity and specificity of the anti-CCP antibody in RA and association of it antibody with disease activity and radiological findings.

Materials and methods

This study was conducted in the outpatient rheumatology unit of the Karadeniz Technical University Medical Faculty, Türkiye. Forty women patients with RA (median age, 48.3 years, range 22–74) who met at least four 1987 American College of Rheumatology (ACR) criteria and 38 women patients with fibromyalgia (median age 44, range31–60), who were considered as control group, were included in this study. Serum samples were obtained from both patient groups with fibromyalgia and RA and were aliquoted and stored at −80°C until assayed. Additionally, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), disease activity score 28 (DAS), visual analog scala (VAS), and human leukocyte antigen (HLA) genotype were recorded in patients with rheumatoid arthritis. Hand radiographs were taken at the beginning of study and radiological assessment was performed by Larsen score.
Serum antibodies directed to the cyclic citrullinated peptide (anti-CCP) were assessed with a commercial enzyme-linked immunosorbent assay (ELISA), (Aida gmbh, Germany, RA/CP detect, Ref 10165) and it was considered as positive if the antibody titer was greater than 15 U/ml.
These results were analyzed by SPSS (version 11.5). Student’s t test for continuous variables was used to examine the significance of differences between the different groups. Non-parametric Mann–Whitney test was used to compare non-paired sets. P-value less than 0.05 was regarded as significant. Correlation between variables was assessed by Spearman’s correlation coefficient and Pearson correlation.

Results

The anti-CCP test demonstrated a specificity of 100% and sensitivity of 50% for RA when compared with controls. The sociodemographic and disease-related characteristics of the patient with rheumatoid arthritis were summarized in Table 1. The mean ± SD age of the patients was 48.3 ± 12.8 years, and all of them were females. The most common treatments received included combination of methotrexate (MTX), sulfosalazine (SSZ) and deltacortril (DTC) (32.5%), followed by the combination of methotrexate and deltacortril (27.5%), sulfasalazine and deltacortril (17.5%), nonsteroidal anti-inflammatory drugs (17.5%) and MTX-hydroxychloroquine (HCQ) (5%). On average, disease duration (S.D.) was 6.8 ± (6.6) years. RF was positive in 26 (65%) patients and negative in 14 (35%) patients. The anti-CCP was positive in 20 (50%) patients and negative in 20 (50%) patients. The mean ± SD titer of the anti-CCP was 104.6 ± 132.2 U/ml. The distribution of anti-CCP titers was demonstrated in Fig. 1. HLA genotypes of the four patients could not be studied. Five (12.5%) patients were in remission. In five (12.5 %) patients, DAS 28 was low, in 20 patients it was median, and in ten patients severely active.
Table 1
Sociodemographic and disease related characteristics of 40 patients with rheumatoid arthritis
Characteristics
 Age, mean ± SD years
48.3 ± 12.8
 BMI, mean ± SD
26.9 ± 4.4
 Female
40 (100)
 RF, mean ± SD
103.5 ± 154
 Anti-CCP, mean ± SD (U/ml)
104.6 ± 132.2
 DAS28, mean ± SD
3.9 ± 1.3
 Remission
5 (12.5)
 Low activity
5 (12.5)
 Median activity
20 (50)
 High activity
10 (25)
 Disease duration ± years
6.8 ± 6.6
 ESR, mean ± SD (mm/1st h)
29.2 ± 22.9
 RF
26/40 (65)
 HLADR3
4/36 (11.1)
 HLADR4
10/36 (27.8)
 VAS, mean ± SD
4.8 ± 1.7
 CRP, mean ± SD (mg/l)
1.9 ± 3.0
Drug treatment
 MTX/DTC
11 (27.5)
 SSZ/DTC
7 (17.5)
 MTX/SS/DTC
13 (32.5)
 MTX/HQC/DTC
2 (5)
 NSAID
7 (17.5)
* Except where indicated otherwise, values are the number (%)
In 18/20 patients (90%) with anti-ccp positive and in 8/20 patients (40%) with anti-CCP negative, RF was positive and there were significant differences between anti-CCP positive and negative patients for rheumatoid factor (< 0.05) (Table 2). The analysis of serological parameters of disease activity (ESR, CRP, DAS 28 and VAS) and disease duration between the anti-CCP positive and negative patients with rheumatoid arthritis showed no significant difference in any parameter (> 0.05). According to radiological assessment of hand radiography by Larsen score (0–100), there was no significant difference between the anti-CCP positive and negative patients with RA. However, the analysis of wrist radiography (0–5) between the anti-CCP positive and negative patients with RA showed significant difference with a higher score in anti-CCP positive patients (< 0.05) (Table 3). There was also no significant correlation between anti-CCP antibody and ESR, CRP, VAS, DAS 28 or radiological assessment. A small but significant correlation was found between RF and anti-CCP antibody (r = 0.3, = 0.02) (Table 4; Fig. 2). Additionally, there was a significant correlation between DAS 28 and RF, ESR, CRP, VAS, radiological assessment of right wrist or left wrist (r = 0.3, = 0.03; r = 0.6, < 0.005; r = 0.4, < 0.005; r = 0.7, < 0.005; r = 0.3, = 0.03; r = 0.4, = 0.02, respectively) (Table 5).
Table 2
Difference in the serological parameter in the CCP-negative versus CCP-positive patients with RA
 
Anti-CCP positive patients (n = 20)
Anti-CCP negative patients (n = 20)
P-value
Age
47.2 ± 14.5
49.5 ± 11
0.593
ESR
25.9 ± 19.4
32.5 ± 26
0.373
CRP
1.5 ± 2.4
2.2 ± 3.7
0.440
Disease duration
7.4 ± 7.5
6.2 ± 5.7
0.614
VAS
5.1 ± 1.7
4.5 ± 1.6
0.313
DAS28
4.1 ± 1.3
3.8 ± 1.4
0.459
RF (+)
18/20 (90)
8/20 (40)
0.001
HLADR3 (+)
1 /19 (5.3)
3/19 (17.6)
0.258
HLADR4 (+)
4 /15 (21.1)
6/17 (35.3)
0.341
Table 3
Difference in the radiologic assessment of hand and wrist by Larsen score in CCP-negative versus CCP-positive patients with RA
 
Anti-CCP positive patients (n = 20)
Anti-CCP negative patients (n = 20)
P-value
Rigt hand score, mean ± SD
12.7 ± 8.4
8.2 ± 5.6
0.051
Right wrist score, mean ± SD
2.4 ± 1.5
1.4 ± 1.3
0.010
Left hand score, mean ± SD
11.2 ± 7.8
10.0 ± 7.6
0.362
Left wrist score, mean ± SD
2.3 ± 2.3
1.4 ± 1.3
0.044
Table 4
The correlation between anti-CCP and other parameters of disease activity
 
X ± SD
Anti-CCP
ESR
29.2 ± 22.9
= 0.54
r = −0.11
CRP
1.9 ± 3.0
= 0.46
r = −0.1
VAS
4.8 ±  1.7
= 0.09
r = −0.02
DAS 28
3.9 ± 1.3
= 0.63
r = 0.07
Left hand
8.9 ± 7.6
= 0.75
r = 0.05
Right hand
8.1 ±  5.6
= 0.37
r = 0.14
Left wrist
1.3 ± 1.2
= 0.49
r = 0.11
Right wrist
1.3 ± 1.2
= 0.10
r = 0.26
RF
103.4 ± 154.1
= 0.02
r = 0.35
Table 5
The correlation of DAS-28 with other parameters of disease activity
 
X ± SD
DAS 28
RF
103.4 ± 154.1
= 0.03
r = 0.3
ESR
29.2 ± 22.9
< 0.005
r = 0.6
CRP
1.9 ± 3.0
< 0.005
r = 0.4
VAS
4.8 ± 1.7
< 0.005
r = 0.7
Right wrist
1.3 ± 1.2
= 0.03
r = 0.3
Left wrist
1.3 ± 1.2
= 0.02
r = 0.4

Discussion

The modern trend of RA treatment has been changed to start treatment as early as possible, based on the concept that early control of inflammation results in reduced joint damage [18]. It therefore is important to differentiate between RA and other forms of arthritis early after the onset of symptoms [19, 20]. Although the 1987 American College of Rheumatology classification criteria for RA [4] are often used in clinical practice as diagnostic tool for RA, they are not very well suited for the diagnosis of early RA [2123]. The ACR criteria rely heavily on the expression of clinical symptoms of RA, but in early RA these clinical parameters are often not (yet) manifest. Therefore, a specific and sensitive (serological) marker, which is present very early in the disease, is needed. Rheumatologists need to be able to target the use of potentially toxic and expensive drugs to those patients, where the benefits clearly outweigh the risks [23, 24]. Therefore a good marker should ideally be able to predict the erosive or nonerosive progression of the disease.
In patients with RA, we found a sensitivity of 50% and specificity of 100% for anti-CCP. Schellekens et al. [25] reported that ELISA methods using the cyclic citrullinated peptide (CCP-ELISA), in a series of 149 RA and 312 control sera, had a diagnostic sensitivity of 48% for a specificity of 96%. Kroot et al. [26] identified 66% positive RA serum samples with CCP-ELISA. Lee and Schur [27] found a sensitivity of 66% and specificity of 90.4%. Dubucquoi et al. [28] describe a sensitivity of 85% and a specificity of 90.9% for anti-CCP. Although the specificity of anti-CCP antibodies in RA is more than 90% in almost all reports, the prevalence (sensitivity) of the same antibodies ranges from 33 to 87.2%. Such a discrepancy in sensitivity might reflect different cutoff levels, racial and genetic backgrounds, as well as the differences of used antigens and detection techniques among reports [29]. Another important point concerning the diagnostic value of CCP is that about 35–40% of the RF-negative RA patients score positively for anti-CCP. In our study, only 2/14 (14.3%) patients with RF-negative RA were positive for anti-CCP antibodies and 12/14 (85.7%) patients with RA were negative.
The value of anti-CCP antibodies and RF for predicting the outcome of RA, clinical signs of disease activity, and the severity of radiographic joint damage has been investigated recently. The studies by van Jaarsveld et al. [30], Kroot et al. [26] and Meyer et al. [15], all support the thesis that RA patients, positive for CCP, develop significanly more radiological damage than CCP-negative patients. Lately, Visser et al. [31] assessed a clinical prediction model in early RA patients for the three forms of arthritis outcome: self-limiting, persistent nonerosive and persistent erosive arthritis in which CCP was strongly associated with erosive arthritis, more than RF. Forslind et al. [32] reported the role of Anti-CCP in the radiological outcome in 379 cases with early RA, and concluded that anti-CCP as well as the baseline Larsen score and ESR was an independent predictor of radiological damage and progression in multiple regression analysis. In our study, CCP positive patients had a higher radiological score than CCP negative patients for radiological assessment of wrist by Larsen method. However, there was no significant difference for radiological assessment of hand by Larsen score.
In addition to the predictive value of CCP concerning radiological damage, Kastbom et al. [16] showed that CCP is good predictor of disease activity. CCP was even better than RF in predicting disease activity over 3 years after the diagnosis of recent onset of RA. Bas et al. showed an association of IgA RF and anti-CCP with clinical signs of disease activity [33, 34]. The high prevalance of anti-CCP in RA patients with extensive disease activity and severe radiological changes, and even more impressively in RA patients who are IgM-RF-negative, suggests that anti-CCP is more useful than the RF alone in the early prediction of disease outcome and disease activity. We found a significant correlation between DAS 28 and RF, ESR, CRP, VAS, radiological assessment of right wrist or left wrist.
There is extensive evidence for the association between certain frequently occurring HLA-DRB1 alleles, the so-called “shared epitope” (SE)-encoding alleles (DRB1*0101, *0102, *0104, *0401, *0404, *0405, *0408, *0413, *0416, and *1001), and susceptibility to RA [35]. Recently, it has been reported that the combination of anti-CCP antibodies and HLA-DRB1 locus antigens is strongly associated with more severe disease progressions [17, 36]. Most recent analyses [37] suggested that the primary association of SE alleles is with the development of erosions, especially in RF-negative individuals [38, 39].
In our study, we could not find correlation between anti-CCP antibody and the serological markers of disease activity (ESR, DAS 28, CRP). There was a small, but significant positive correlation with anti-CCP and RF. Furthermore, we could find no significant difference between anti-CCP negative and anti-CCP-positive patients comparing ESR, CRP, HLA genotype, DAS. However, there was a significant differences between anti-CCP (+) and anti-CCP (−) RA patients for RF.
In conclusion, early development of erosive disease in RA is associated with the presence of several autoantibodies and the IgM RF is stil mostly used as a screening marker in the diagnosis of RA. However, the anti-CCP antibody assays have a comparable sensitivity in the diagnosis of RA but a much higher specifity. Further research, however, will be necesssary to elucidate the exact mechanism and the significance of protein citrullination in etiopathogenesis of RA.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://​creativecommons.​org/​licenses/​by-nc/​2.​0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Literatur
2.
Zurück zum Zitat Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK (1984) Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27:864–872PubMedCrossRef Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK (1984) Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 27:864–872PubMedCrossRef
3.
Zurück zum Zitat Goodson N (2002) Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 14:115–120PubMedCrossRef Goodson N (2002) Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 14:115–120PubMedCrossRef
4.
Zurück zum Zitat Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
5.
Zurück zum Zitat Vallbracht I, Helmke K (2005) Additional diagnostic and clinical value of anti-cylic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Autoimmunity Rev 4:389–394CrossRef Vallbracht I, Helmke K (2005) Additional diagnostic and clinical value of anti-cylic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Autoimmunity Rev 4:389–394CrossRef
6.
Zurück zum Zitat Mottonen TT (1988) Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 47:648–653PubMedCrossRef Mottonen TT (1988) Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 47:648–653PubMedCrossRef
7.
Zurück zum Zitat van der Heijde DM (1995) Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 34 (Suppl 2):1–8 van der Heijde DM (1995) Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 34 (Suppl 2):1–8
8.
Zurück zum Zitat Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27PubMedCrossRef Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27PubMedCrossRef
9.
10.
Zurück zum Zitat Eggeland T, Munthe E (1983) The role of the laboratory in rheumatology, rheumatoid factors. Clin Rheum Dis 9:135–160 Eggeland T, Munthe E (1983) The role of the laboratory in rheumatology, rheumatoid factors. Clin Rheum Dis 9:135–160
11.
Zurück zum Zitat Smolen JS (1996) Autoantibodies in rheumatoid arthritis. In: van Venrooij WJ, Maini RN, (eds) Manual of biological markers of disease, Section C1.1/1–C1.1/18. Kluwer, Dordrecht Smolen JS (1996) Autoantibodies in rheumatoid arthritis. In: van Venrooij WJ, Maini RN, (eds) Manual of biological markers of disease, Section C1.1/1–C1.1/18. Kluwer, Dordrecht
12.
Zurück zum Zitat Thorsteinsson J, Bjfrnsson OJ, Kolbeinsson A, Allander E, Sigfusson N, Olafsson O (1975) A population study of rheumatoid factor in Iceland. A 5 year follow-up of 50 women with rheumatoid factor (RF). Ann Clin Res 7:183–194PubMed Thorsteinsson J, Bjfrnsson OJ, Kolbeinsson A, Allander E, Sigfusson N, Olafsson O (1975) A population study of rheumatoid factor in Iceland. A 5 year follow-up of 50 women with rheumatoid factor (RF). Ann Clin Res 7:183–194PubMed
13.
Zurück zum Zitat Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50:709–715PubMedCrossRef Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL et al (2004) Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 50:709–715PubMedCrossRef
14.
Zurück zum Zitat Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749PubMedCrossRef Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741–2749PubMedCrossRef
15.
Zurück zum Zitat Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A et al (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126PubMedCrossRef Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A et al (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120–126PubMedCrossRef
16.
Zurück zum Zitat Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089PubMedCrossRef Kastbom A, Strandberg G, Lindroos A, Skogh T (2004) Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 63:1085–1089PubMedCrossRef
17.
Zurück zum Zitat van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E et al (2004) Association between HLA class IIgenes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50:2113–2121PubMedCrossRef van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E et al (2004) Association between HLA class IIgenes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50:2113–2121PubMedCrossRef
18.
Zurück zum Zitat Emery P (1994) The optimal management of early rheumatoid disease: the key to preventing disability. Br J Rheumatol 33:765–768PubMedCrossRef Emery P (1994) The optimal management of early rheumatoid disease: the key to preventing disability. Br J Rheumatol 33:765–768PubMedCrossRef
19.
Zurück zum Zitat Lındovist E, Eberhardt K, Bendtzen K et al (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201CrossRef Lındovist E, Eberhardt K, Bendtzen K et al (2005) Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 64:196–201CrossRef
20.
Zurück zum Zitat Vısser H (2005) Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol 19:55–72PubMedCrossRef Vısser H (2005) Early diagnosis of rheumatoid arthritis. Best Pract Res Clin Rheumatol 19:55–72PubMedCrossRef
21.
Zurück zum Zitat Kaarela K, Kauppi MJ, Lehtinen KE (1995) The value of the ACR 1987 criteria in very early rheumatoid arthritis. Scand J Rheumatol 24:279–281PubMedCrossRef Kaarela K, Kauppi MJ, Lehtinen KE (1995) The value of the ACR 1987 criteria in very early rheumatoid arthritis. Scand J Rheumatol 24:279–281PubMedCrossRef
22.
Zurück zum Zitat Saraux A, Berthelot JM, Chales G, Le Henaff C, Thorel JB, Hoang S et al (2001) Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 44:2485–2491PubMedCrossRef Saraux A, Berthelot JM, Chales G, Le Henaff C, Thorel JB, Hoang S et al (2001) Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 44:2485–2491PubMedCrossRef
23.
Zurück zum Zitat van Venrooij WJ, Hazes JM, Visser H (2002) Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 60:383–388PubMed van Venrooij WJ, Hazes JM, Visser H (2002) Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 60:383–388PubMed
24.
Zurück zum Zitat Kirwan JR, Quilty B (1997) Prognostic criteria in rheumatoid arthritis: can we predict which patients will require specific anti-rheumatoid treatment? Clin Exp Rheumatol 15(Suppl 17):S15–S25PubMed Kirwan JR, Quilty B (1997) Prognostic criteria in rheumatoid arthritis: can we predict which patients will require specific anti-rheumatoid treatment? Clin Exp Rheumatol 15(Suppl 17):S15–S25PubMed
25.
Zurück zum Zitat Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef
26.
Zurück zum Zitat Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. ArthritisRheum 43:1831–1835 Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL (2000) The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. ArthritisRheum 43:1831–1835
27.
Zurück zum Zitat Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assays in patients with rheumatic diseases. Ann Rheum Dis 62:870–874PubMedCrossRef Lee DM, Schur PH (2003) Clinical utility of the anti-CCP assays in patients with rheumatic diseases. Ann Rheum Dis 62:870–874PubMedCrossRef
28.
Zurück zum Zitat Dubucquoı S, Solau-Gervaıs E, Lefranc D et al (2004) Evaluation of anti-citrullinatedfilagrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63:415–419PubMedCrossRef Dubucquoı S, Solau-Gervaıs E, Lefranc D et al (2004) Evaluation of anti-citrullinatedfilagrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 63:415–419PubMedCrossRef
29.
Zurück zum Zitat Mımori T (2005) Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med 44:1112–1126CrossRef Mımori T (2005) Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med 44:1112–1126CrossRef
30.
Zurück zum Zitat van Jaarsveld CHM, ter Borg EJ, Jacobs JWG, Schellekens GA, Gmeling-Meyling FHJ, van Booma-Frankfort C et al (1999) The prognostic value of the antiperinuclear factor, anticitrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 17:689–697PubMed van Jaarsveld CHM, ter Borg EJ, Jacobs JWG, Schellekens GA, Gmeling-Meyling FHJ, van Booma-Frankfort C et al (1999) The prognostic value of the antiperinuclear factor, anticitrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 17:689–697PubMed
31.
Zurück zum Zitat Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) Arthritis. Arthritis Rheum 46:357–365PubMedCrossRef Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) Arthritis. Arthritis Rheum 46:357–365PubMedCrossRef
32.
Zurück zum Zitat Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B (2004) BARFOT Study Group. Prediction of radiological outcome in early reumatoid arthritis in clinic paractice, role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095PubMedCrossRef Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B (2004) BARFOT Study Group. Prediction of radiological outcome in early reumatoid arthritis in clinic paractice, role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 63:1090–1095PubMedCrossRef
33.
Zurück zum Zitat Bas S, Perneger T.V, Seitz M et al (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 41:809–814PubMedCrossRef Bas S, Perneger T.V, Seitz M et al (2002) Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 41:809–814PubMedCrossRef
34.
Zurück zum Zitat Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680PubMedCrossRef Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680PubMedCrossRef
35.
Zurück zum Zitat Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205–13. (discussıon-HLA DR)PubMedCrossRef Gregersen PK, Silver J, Winchester RJ (1987) The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30:1205–13. (discussıon-HLA DR)PubMedCrossRef
36.
Zurück zum Zitat Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooji WJ et al (2004) A combination of autoantibodies to cylic citrullinatedpeptide (CCP) and HLA-DRB1 locus antigens iss strogly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 6(4):R303–R308PubMedCrossRef Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooji WJ et al (2004) A combination of autoantibodies to cylic citrullinatedpeptide (CCP) and HLA-DRB1 locus antigens iss strogly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 6(4):R303–R308PubMedCrossRef
37.
Zurück zum Zitat Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA (2004) Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 50:400–412PubMedCrossRef Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA (2004) Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 50:400–412PubMedCrossRef
38.
Zurück zum Zitat El-Gabalawy HS, Goldbach-Mansky R, Smith D II, Arayssi T, Bale S, Gulko P, Yarboro C, Wilder RL, Klippel JH, Schumacher HR Jr (1999) Association of HLA alleles and clinical features in patients with synovitis of recent onset. Arthritis Rheum 42:1696–1705PubMedCrossRef El-Gabalawy HS, Goldbach-Mansky R, Smith D II, Arayssi T, Bale S, Gulko P, Yarboro C, Wilder RL, Klippel JH, Schumacher HR Jr (1999) Association of HLA alleles and clinical features in patients with synovitis of recent onset. Arthritis Rheum 42:1696–1705PubMedCrossRef
39.
Zurück zum Zitat Harrison B, Thomson W, Symmons D, Ollier B, Wiles N, Payton T, Barrett E, Silman A (1999) The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis Rheum 42:2174–2183PubMedCrossRef Harrison B, Thomson W, Symmons D, Ollier B, Wiles N, Payton T, Barrett E, Silman A (1999) The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis Rheum 42:2174–2183PubMedCrossRef
Metadaten
Titel
The association of anti-CCP antibodies with disease activity in rheumatoid arthritis
verfasst von
Münevver Serdaroğlu
Haşim Çakırbay
Orhan Değer
Sevil Cengiz
Sibel Kul
Publikationsdatum
01.08.2008
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 10/2008
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0570-3

Weitere Artikel der Ausgabe 10/2008

Rheumatology International 10/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.